Metabolic syndrome in HD patients: Association with body composition, nutritional status, inflammation and serum iron

Internal Medicine

Volumn 46, Issue 13, 2007, Pages 945-951

  Rasic Milutinovic, Zorica ^a   Perunicic, Gordana ^a   Pljesa, Steva ^a   Gluvic, Zoran ^a   Ilic, Mirka ^b   Stokić, Edith ^c  

^a University Children's Hospital   (Yugoslavia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Clinical Center of Novi Sad   (Yugoslavia)

Author keywords

Adipocitokynes TNF alpha; End stage renal disease; IL 6; Iron; Metabolic syndrome; SGA score

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; FERRITIN; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; IRON; PARATHYROID HORMONE; PHOSPHATE; TRANSFERRIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; IRON BLOOD LEVEL; KIDNEY FAILURE; MALE; METABOLIC SYNDROME X; NUTRITIONAL STATUS; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RATING SCALE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITIONAL STATUS; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 34547864594     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0092     Document Type: Article

References (28)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365: 1415-1428, 2005.
2. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48: 1684-1699, 2005.
3. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-age men: the 22-year follow-up results of the Helsinki Policemen Study. Arteriscler Thromb Vasc Bio 20: 538-544, 2000.
4. McNeill AM, Rosamond DW, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28: 385-390, 2005.
5. Rasic-Milutinovic Z, Peruničić G, Plješa S, et al. Is insulin independent predictor of mortality in hemodialysis patients. Yugoslav Medical Biochemistry 23: 43-49, 2004.
6. Wisse BE. Inflammatory syndrome: the role of adipose tissue cytokines in metabolic desorders link to obesity. J Am Soc Nephrol 15: 2792-2800, 2004.
7. Dressner A. Insulin mediated glucose uptake in muscle, in the absence of fatty acids and in the presence of LCFACoA. J Clin Invest 103: 253-259, 1999.
8. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 4: 487-492, 2003.
9. Kautzky-Willer A, Pacini G, Barnas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients.. Kidney In 47: 200-206, 1995.
10. 3 Corrects insulin and lipid abnormalities in uremia. Kidney Int 53: 1353-1357, 1998.
11. Rasic-Milutinovic Z, Peruničić-Peković G, Plješa S, Komadina L, Gluvi ć Z, Milić N. Impaired insulin sensitivity and insulin secretion in hemodialysis patients with and without secondary hyperparathyroidism. Malta Medical Journal 16: 18-22, 2004.
12. Zoui P, Hakim RM. The effects of the dialysis membrane on cytokine release. J Am Soc Nephro 4: 1711-1718, 1994.
13. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647, 1992.
14. Igaki N, Takashima M, Ohyama M, et al. The beneficial effect of effective control of anemia on hyperinsulinemia and hypoxemia in a hemodialysis patient with corrected transposition of the great arteries. Clin Exp Nephro 8: 163-167, 2004.
15. Feldman HI, Santana J, Guo W, et al. Iron administration and clinical outcome in hemodialysis patients. J Am Soc Nephrol 13: 734-744, 2002.
16. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998.
17. Fernandez-Real JM, Penarroja G, Gastro A, Garcia-Bragado F, Hemandez I, Ricart W. Blood letting in high-ferritin type 2 diabetes mellitus. Effects on insulin sensitivity and beta cell function. Diabetes 51: 1000-1004, 2002.
18. Fernandez-Real JM, Lopez-Bermejo A, Wifredo R. Iron stores, blood donation and insulin sensitivity and secretion. Clin Chem 51: 1201-1205, 2005.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
20. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 27: 2222-2228, 2004.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
22. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
23. Vozarova. B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Partley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9: 414-417, 2001.
24. Collins T, Cybulsky MI. NF-kB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107: 255-264, 2001.
25. Kalantar-Zadeh K, Rodrigez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in hemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004.
26. Drucke T, Witko-Sarsat V, Massay Z. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002.
27. Turk U, Akbulut M, Yildiz A, et al. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodalysis patients: the effect on serum IL1 and IL6 and bone mineral density. Nefro 90: 188-194, 2002.
28. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplan 19 (5): 67-72, 2004.